PAVmed (NASDAQ:PAVM) & Artivion (NYSE:AORT) Head-To-Head Contrast

PAVmed (NASDAQ:PAVM – Get Rating) and Artivion (NYSE:AORT – Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

Profitability

This table compares PAVmed and Artivion’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PAVmed	N/A	-276.05%	-81.61%
Artivion	-9.17%	0.65%	0.24%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for PAVmed and Artivion, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PAVmed	0	1	1	0	2.50
Artivion	0	1	3	0	2.75

PAVmed currently has a consensus target price of $3.75, suggesting a potential upside of 737.80%. Artivion has a consensus target price of $22.50, suggesting a potential upside of 49.90%. Given PAVmed’s higher possible upside, analysts plainly believe PAVmed is more favorable than Artivion.

Risk & Volatility

PAVmed has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500. Comparatively, Artivion has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500.

Institutional & Insider Ownership

14.0% of PAVmed shares are held by institutional investors. Comparatively, 88.0% of Artivion shares are held by institutional investors. 13.2% of PAVmed shares are held by company insiders. Comparatively, 6.6% of Artivion shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares PAVmed and Artivion’s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PAVmed	$380,000.00	121.90	-$88.98 million	($1.00)	-0.45
Artivion	$313.79 million	1.96	-$19.19 million	($0.73)	-20.56

Artivion has higher revenue and earnings than PAVmed. Artivion is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks.

Summary

Artivion beats PAVmed on 9 of the 14 factors compared between the two stocks.

About PAVmed

(Get Rating)

PAVmed, Inc. is a commercial-stage technology medical device company, which engages in the commercialization of medical technologies. It operates through the following divisions: Medical Devices, Diagnostics, Digital Health, and Emerging Innovations. Its products include cell collection devices, esophageal DNA tests, carpal tunnel release, implantable intraosseous vascular access devices, and antimicrobial resorbable ear tubes. The company was founded on June 26, 2014 and is headquartered in New York, NY.

About Artivion

(Get Rating)

Artivion, Inc. engages in the research and development of solutions which address cardiac and vascular surgeons’ clinical challenges in treating patients with aortic diseases. Its products include aortic stents and stent grafts, prosthetic heart valves, cryopreserved cardiac and vascular allografts, and surgical sealants. It operates through the Medical Devices and Preservation Services segments. The Medical Devices segment includes aortic stents and stent grafts, surgical sealants, and On-X products. The Preservation Services segment offers cardiac and vascular tissue preservation services. The company was founded on January 19, 1984 and is headquartered in Kennesaw, GA.